+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Pharmacovigilance Market - Global Forecast 2026-2032- Product Image
Pharmacovigilance Market - Global Forecast 2026-2032- Product Image
New

Pharmacovigilance Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 192 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 5306611
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The pharmacovigilance market is undergoing significant transformation as regulatory requirements, technological advancements, and increased collaboration across sectors present new challenges and opportunities for patient safety and compliance. Senior decision-makers must now navigate a highly interconnected landscape that demands agile strategies for both regulatory adherence and operational effectiveness.

Market Snapshot: Global Pharmacovigilance Market Value and Growth

The Pharmacovigilance Market expanded from USD 11.84 billion in 2025 to USD 13.71 billion in 2026. It is projected to sustain a compound annual growth rate (CAGR) of 16.34%, ultimately reaching USD 34.17 billion by 2032. This growth is driven by intensifying global regulatory oversight, rising adoption of advanced technologies, and increasing complexity in therapeutic development, all of which raise the bar for drug safety monitoring and compliance frameworks. The evolving market landscape is compelling organizations to reassess their investment priorities and integrate capabilities that ensure consistent, enterprise-wide vigilance.

Scope & Segmentation of the Pharmacovigilance Market

  • Type: Cohort event monitoring, EHR mining, intensified ADR reporting, spontaneous reporting, targeted spontaneous reporting. Each method addresses distinct surveillance priorities, allowing for adaptable pharmacovigilance strategies suited to varying risk profiles.
  • Product Life Cycle: Pre-clinical, Phase I, Phase II, Phase III, Phase IV. Pharmacovigilance interventions are customized at every product lifecycle stage, ensuring comprehensive monitoring from early development through post-market surveillance.
  • Delivery Mode: In-house, outsourced. Organizations balance cost, expertise, and control by selecting flexible delivery models aligned to case volume and complexity.
  • Process Flow: Case data management, risk management systems, signal detection. Each function provides an integrated approach to adverse event tracking, risk evaluation, and medical review, supporting timely regulatory submissions and informed decision-making.
  • Therapeutic Area: Cardiovascular, infectious diseases, neurology, oncology, respiratory. This segmentation enables teams to prioritize interventions in high-need areas and address regulatory nuances unique to each therapy.
  • End User: Biotechnology companies, medical device manufacturers, pharmaceuticals. Stakeholders in these sectors rely on tailored pharmacovigilance solutions to address varying compliance and operational needs.
  • Region: Americas, Europe, Middle East & Africa, Asia-Pacific. Regional segmentation supports locally compliant approaches while maintaining global standards, factoring in jurisdictional variation in regulation and data privacy.
  • Technologies: Artificial intelligence, machine learning, automation tools, data pipelines, real-world data integration. These technologies transform traditional reporting and risk detection workflows, enabling greater efficiency and predictive insight.

This in-depth segmentation facilitates targeted capability building and investment direction, helping organizations navigate the complexity of evolving product pipelines and global regulation.

Key Takeaways for Senior Decision-Makers

  • Pharmacovigilance now extends well beyond reactive adverse event reporting, with increasing focus on proactive risk management and integration of real-world evidence.
  • Collaboration between clinical, regulatory, and data science teams enhances the reliability and speed of safety surveillance, while supporting rapid pattern recognition for emerging risks.
  • Adopting hybrid operating models, blending in-house leadership with selective outsourcing, allows organizations to scale efficiently, leverage specialized expertise, and address fluctuating case workload.
  • The adoption of artificial intelligence, automation, and machine learning is expediting data processing, enabling more effective identification and management of relevant safety signals from diverse data streams.
  • Distinct regional regulatory requirements and unequal data maturity demand that global organizations maintain adaptable approaches while meeting both centralized and localized compliance standards.
  • Continuous workforce upskilling and investment in regulatory intelligence are paramount for staying ahead of evolving industry requirements and ensuring consistent operational oversight.

Tariff Impact on Pharmacovigilance Sourcing and Operations

Recent tariff changes in the United States have heightened operational expenses for pharmacovigilance providers operating across borders. These developments have led organizations to diversify supplier relationships and prioritize the localization of essential activities. Such responses enhance business continuity and support ongoing compliance with evolving data residency, privacy, and contractual standards. Procurement strategies now account for potential service disruptions, emphasizing nearshore or onshore data processing to manage emerging risks more effectively.

Methodology & Data Sources

This report relies on a comprehensive mixed-methods methodology. Primary research includes structured interviews with leading experts in safety and regulation, complemented by secondary analysis of scientific literature and regulatory guidance. In addition, robust capability profiling and multi-source data triangulation underpin each technology and market claim, ensuring reliability and actionability.

Why This Report Matters

  • Supports strategic investment decisions by offering actionable insights into shifting pharmacovigilance processes, technology deployment, and regulatory changes.
  • Delivers executives clear direction for governance, sourcing, and operational compliance across multiple regions and therapeutic areas.
  • Enables organizations to build resilience and future readiness using tailored recommendations aligned to their product portfolios and local market demands.

Conclusion

Pharmacovigilance leaders face a landscape marked by regulatory sophistication, technology-driven change, and global operational challenge. This report provides decision-makers with the clarity and context essential to promote robust compliance, safeguard patient outcomes, and maintain operational strength.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Pharmacovigilance Market, by Type
8.1. Cohort Event Monitoring
8.2. EHR Mining
8.3. Intensified ADR Reporting
8.4. Spontaneous Reporting
8.5. Targeted Spontaneous Reporting
9. Pharmacovigilance Market, by Product Life Cycle
9.1. Phase I
9.2. Phase II
9.3. Phase III
9.4. Phase IV
9.5. Pre-clinical
10. Pharmacovigilance Market, by Delivery Mode
10.1. In-house
10.2. Outsourced
11. Pharmacovigilance Market, by Process Flow
11.1. Case Data Management
11.1.1. Case Data Analysis
11.1.2. Case Logging
11.1.3. Medical Reviewing & Reporting
11.2. Risk Management System
11.2.1. Risk Evaluation System
11.2.2. Risk Mitigation System
11.3. Signal Detection
11.3.1. Adverse Event Analysis
11.3.2. Adverse Event Logging
11.3.3. Adverse Event Review & Reporting
12. Pharmacovigilance Market, by Therapeutic Area
12.1. Cardiovascular
12.2. Infectious Diseases
12.3. Neurology
12.4. Oncology
12.5. Respiratory
13. Pharmacovigilance Market, by End-user
13.1. Biotechnology Companies
13.2. Medical Device Manufacturers
13.3. Pharmaceuticals
14. Pharmacovigilance Market, by Region
14.1. Americas
14.1.1. North America
14.1.2. Latin America
14.2. Europe, Middle East & Africa
14.2.1. Europe
14.2.2. Middle East
14.2.3. Africa
14.3. Asia-Pacific
15. Pharmacovigilance Market, by Group
15.1. ASEAN
15.2. GCC
15.3. European Union
15.4. BRICS
15.5. G7
15.6. NATO
16. Pharmacovigilance Market, by Country
16.1. United States
16.2. Canada
16.3. Mexico
16.4. Brazil
16.5. United Kingdom
16.6. Germany
16.7. France
16.8. Russia
16.9. Italy
16.10. Spain
16.11. China
16.12. India
16.13. Japan
16.14. Australia
16.15. South Korea
17. United States Pharmacovigilance Market
18. China Pharmacovigilance Market
19. Competitive Landscape
19.1. Market Concentration Analysis, 2025
19.1.1. Concentration Ratio (CR)
19.1.2. Herfindahl Hirschman Index (HHI)
19.2. Recent Developments & Impact Analysis, 2025
19.3. Product Portfolio Analysis, 2025
19.4. Benchmarking Analysis, 2025
19.5. Accenture, PLC
19.6. Bristol-Myers Squibb Company
19.7. Capgemini SE
19.8. ClinChoice
19.9. F. Hoffmann-La Roche AG
19.10. GlaxoSmithKline PLC
19.11. HCL Technologies Limited
19.12. ICON PLC
19.13. Infosys Limited
19.14. International Business Machines Corporation
19.15. IQVIA Inc.
19.16. ITclinical
19.17. Laboratory Corporation of America Holdings
19.18. Linical Co., Ltd.
19.19. Novartis AG
19.20. Oracle Corporation
19.21. Parexel International
19.22. Pfizer Inc.
19.23. Quanticate International limited
19.24. Sanofi S.A.
19.25. Syneos Health
19.26. TAKE Solutions Limited
19.27. TATA Consultancy Services Limited
19.28. Wipro Limited
List of Figures
FIGURE 1. GLOBAL PHARMACOVIGILANCE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL PHARMACOVIGILANCE MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL PHARMACOVIGILANCE MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 13. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 14. CHINA PHARMACOVIGILANCE MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL PHARMACOVIGILANCE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY COHORT EVENT MONITORING, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY COHORT EVENT MONITORING, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY COHORT EVENT MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY EHR MINING, BY REGION, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY EHR MINING, BY GROUP, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY EHR MINING, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY INTENSIFIED ADR REPORTING, BY REGION, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY INTENSIFIED ADR REPORTING, BY GROUP, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY INTENSIFIED ADR REPORTING, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY SPONTANEOUS REPORTING, BY REGION, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY SPONTANEOUS REPORTING, BY GROUP, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY SPONTANEOUS REPORTING, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY TARGETED SPONTANEOUS REPORTING, BY REGION, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY TARGETED SPONTANEOUS REPORTING, BY GROUP, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY TARGETED SPONTANEOUS REPORTING, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PHASE I, BY REGION, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PHASE I, BY GROUP, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PHASE I, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PHASE II, BY REGION, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PHASE II, BY GROUP, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PHASE II, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PHASE III, BY REGION, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PHASE III, BY GROUP, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PHASE III, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PHASE IV, BY REGION, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PHASE IV, BY GROUP, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PHASE IV, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PRE-CLINICAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PRE-CLINICAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PRE-CLINICAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY IN-HOUSE, BY REGION, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY IN-HOUSE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY IN-HOUSE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY OUTSOURCED, BY REGION, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY OUTSOURCED, BY GROUP, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY OUTSOURCED, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, BY REGION, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA ANALYSIS, BY REGION, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA ANALYSIS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA ANALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY CASE LOGGING, BY REGION, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY CASE LOGGING, BY GROUP, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY CASE LOGGING, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY MEDICAL REVIEWING & REPORTING, BY REGION, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY MEDICAL REVIEWING & REPORTING, BY GROUP, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY MEDICAL REVIEWING & REPORTING, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, BY REGION, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, BY GROUP, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY RISK EVALUATION SYSTEM, BY REGION, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY RISK EVALUATION SYSTEM, BY GROUP, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY RISK EVALUATION SYSTEM, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY RISK MITIGATION SYSTEM, BY REGION, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY RISK MITIGATION SYSTEM, BY GROUP, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY RISK MITIGATION SYSTEM, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, BY REGION, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY ADVERSE EVENT ANALYSIS, BY REGION, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY ADVERSE EVENT ANALYSIS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY ADVERSE EVENT ANALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY ADVERSE EVENT LOGGING, BY REGION, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY ADVERSE EVENT LOGGING, BY GROUP, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY ADVERSE EVENT LOGGING, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY ADVERSE EVENT REVIEW & REPORTING, BY REGION, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY ADVERSE EVENT REVIEW & REPORTING, BY GROUP, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY ADVERSE EVENT REVIEW & REPORTING, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY NEUROLOGY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY RESPIRATORY, BY REGION, 2018-2032 (USD MILLION)
TABLE 92. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY RESPIRATORY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 93. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY RESPIRATORY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 94. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 95. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 96. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 97. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 98. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY MEDICAL DEVICE MANUFACTURERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 99. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY MEDICAL DEVICE MANUFACTURERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 100. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY MEDICAL DEVICE MANUFACTURERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 101. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PHARMACEUTICALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 102. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PHARMACEUTICALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 103. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PHARMACEUTICALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 104. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 105. AMERICAS PHARMACOVIGILANCE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 106. AMERICAS PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 107. AMERICAS PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2032 (USD MILLION)
TABLE 108. AMERICAS PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 109. AMERICAS PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2032 (USD MILLION)
TABLE 110. AMERICAS PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2032 (USD MILLION)
TABLE 111. AMERICAS PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2032 (USD MILLION)
TABLE 112. AMERICAS PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2032 (USD MILLION)
TABLE 113. AMERICAS PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 114. AMERICAS PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 115. NORTH AMERICA PHARMACOVIGILANCE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 116. NORTH AMERICA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 117. NORTH AMERICA PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2032 (USD MILLION)
TABLE 118. NORTH AMERICA PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 119. NORTH AMERICA PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2032 (USD MILLION)
TABLE 120. NORTH AMERICA PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2032 (USD MILLION)
TABLE 121. NORTH AMERICA PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2032 (USD MILLION)
TABLE 122. NORTH AMERICA PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2032 (USD MILLION)
TABLE 123. NORTH AMERICA PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 124. NORTH AMERICA PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 125. LATIN AMERICA PHARMACOVIGILANCE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 126. LATIN AMERICA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 127. LATIN AMERICA PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2032 (USD MILLION)
TABLE 128. LATIN AMERICA PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 129. LATIN AMERICA PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2032 (USD MILLION)
TABLE 130. LATIN AMERICA PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2032 (USD MILLION)
TABLE 131. LATIN AMERICA PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2032 (USD MILLION)
TABLE 132. LATIN AMERICA PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2032 (USD MILLION)
TABLE 133. LATIN AMERICA PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 134. LATIN AMERICA PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 135. EUROPE, MIDDLE EAST & AFRICA PHARMACOVIGILANCE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 136. EUROPE, MIDDLE EAST & AFRICA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 137. EUROPE, MIDDLE EAST & AFRICA PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2032 (USD MILLION)
TABLE 138. EUROPE, MIDDLE EAST & AFRICA PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 139. EUROPE, MIDDLE EAST & AFRICA PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2032 (USD MILLION)
TABLE 140. EUROPE, MIDDLE EAST & AFRICA PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2032 (USD MILLION)
TABLE 141. EUROPE, MIDDLE EAST & AFRICA PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2032 (USD MILLION)
TABLE 142. EUROPE, MIDDLE EAST & AFRICA PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2032 (USD MILLION)
TABLE 143. EUROPE, MIDDLE EAST & AFRICA PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 144. EUROPE, MIDDLE EAST & AFRICA PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 145. EUROPE PHARMACOVIGILANCE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 146. EUROPE PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 147. EUROPE PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2032 (USD MILLION)
TABLE 148. EUROPE PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 149. EUROPE PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2032 (USD MILLION)
TABLE 150. EUROPE PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2032 (USD MILLION)
TABLE 151. EUROPE PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2032 (USD MILLION)
TABLE 152. EUROPE PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2032 (USD MILLION)
TABLE 153. EUROPE PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 154. EUROPE PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 155. MIDDLE EAST PHARMACOVIGILANCE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 156. MIDDLE EAST PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 157. MIDDLE EAST PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2032 (USD MILLION)
TABLE 158. MIDDLE EAST PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 159. MIDDLE EAST PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2032 (USD MILLION)
TABLE 160. MIDDLE EAST PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2032 (USD MILLION)
TABLE 161. MIDDLE EAST PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2032 (USD MILLION)
TABLE 162. MIDDLE EAST PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2032 (USD MILLION)
TABLE 163. MIDDLE EAST PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 164. MIDDLE EAST PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 165. AFRICA PHARMACOVIGILANCE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 166. AFRICA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 167. AFRICA PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2032 (USD MILLION)
TABLE 168. AFRICA PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 169. AFRICA PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2032 (USD MILLION)
TABLE 170. AFRICA PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2032 (USD MILLION)
TABLE 171. AFRICA PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2032 (USD MILLION)
TABLE 172. AFRICA PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2032 (USD MILLION)
TABLE 173. AFRICA PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 174. AFRICA PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 175. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 176. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 177. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2032 (USD MILLION)
TABLE 178. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 179. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2032 (USD MILLION)
TABLE 180. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2032 (USD MILLION)
TABLE 181. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2032 (USD MILLION)
TABLE 182. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2032 (USD MILLION)
TABLE 183. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 184. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 185. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 186. ASEAN PHARMACOVIGILANCE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 187. ASEAN PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 188. ASEAN PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2032 (USD MILLION)
TABLE 189. ASEAN PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 190. ASEAN PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2032 (USD MILLION)
TABLE 191. ASEAN PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2032 (USD MILLION)
TABLE 192. ASEAN PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2032 (USD MILLION)
TABLE 193. ASEAN PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2032 (USD MILLION)
TABLE 194. ASEAN PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 195. ASEAN PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 196. GCC PHARMACOVIGILANCE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 197. GCC PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 198. GCC PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2032 (USD MILLION)
TABLE 199. GCC PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 200. GCC PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2032 (USD MILLION)
TABLE 201. GCC PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2032 (USD MILLION)
TABLE 202. GCC PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2032 (USD MILLION)
TABLE 203. GCC PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2032 (USD MILLION)
TABLE 204. GCC PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 205. GCC PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 206. EUROPEAN UNION PHARMACOVIGILANCE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 207. EUROPEAN UNION PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 208. EUROPEAN UNION PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2032 (USD MILLION)
TABLE 209. EUROPEAN UNION PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 210. EUROPEAN UNION PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2032 (USD MILLION)
TABLE 211. EUROPEAN UNION PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2032 (USD MILLION)
TABLE 212. EUROPEAN UNION PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2032 (USD MILLION)
TABLE 213. EUROPEAN UNION PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2032 (USD MILLION)
TABLE 214. EUROPEAN UNION PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 215. EUROPEAN UNION PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 216. BRICS PHARMACOVIGILANCE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 217. BRICS PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 218. BRICS PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2032 (USD MILLION)
TABLE 219. BRICS PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 220. BRICS PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2032 (USD MILLION)
TABLE 221. BRICS PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2032 (USD MILLION)
TABLE 222. BRICS PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2032 (USD MILLION)
TABLE 223. BRICS PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2032 (USD MILLION)
TABLE 224. BRICS PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 225. BRICS PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 226. G7 PHARMACOVIGILANCE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 227. G7 PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 228. G7 PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2032 (USD MILLION)
TABLE 229. G7 PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 230. G7 PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2032 (USD MILLION)
TABLE 231. G7 PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2032 (USD MILLION)
TABLE 232. G7 PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2032 (USD MILLION)
TABLE 233. G7 PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2032 (USD MILLION)
TABLE 234. G7 PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 235. G7 PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 236. NATO PHARMACOVIGILANCE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 237. NATO PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 238. NATO PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2032 (USD MILLION)
TABLE 239. NATO PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 240. NATO PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2032 (USD MILLION)
TABLE 241. NATO PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2032 (USD MILLION)
TABLE 242. NATO PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2032 (USD MILLION)
TABLE 243. NATO PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2032 (USD MILLION)
TABLE 244. NATO PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 245. NATO PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 246. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 247. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 248. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 249. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2032 (USD MILLION)
TABLE 250. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 251. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2032 (USD MILLION)
TABLE 252. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2032 (USD MILLION)
TABLE 253. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2032 (USD MILLION)
TABLE 254. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2032 (USD MILLION)
TABLE 255. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 256. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 257. CHINA PHARMACOVIGILANCE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 258. CHINA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 259. CHINA PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2032 (USD MILLION)
TABLE 260. CHINA PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 261. CHINA PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2032 (USD MILLION)
TABLE 262. CHINA PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2032 (USD MILLION)
TABLE 263. CHINA PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2032 (USD MILLION)
TABLE 264. CHINA PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2032 (USD MILLION)
TABLE 265. CHINA PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 266. CHINA PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this Pharmacovigilance market report include:
  • Accenture, PLC
  • Bristol-Myers Squibb Company
  • Capgemini SE
  • ClinChoice
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • HCL Technologies Limited
  • ICON PLC
  • Infosys Limited
  • International Business Machines Corporation
  • IQVIA Inc.
  • ITclinical
  • Laboratory Corporation of America Holdings
  • Linical Co., Ltd.
  • Novartis AG
  • Oracle Corporation
  • Parexel International
  • Pfizer Inc.
  • Quanticate International limited
  • Sanofi S.A.
  • Syneos Health
  • TAKE Solutions Limited
  • TATA Consultancy Services Limited
  • Wipro Limited

Table Information

Report AttributeDetails
No. of Pages192
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 13.71 Billion
Forecasted Market Value ( USD ) by 2032 $ 34.17 Billion
Compound Annual Growth Rate16.3%
Regions CoveredGlobal
No. of Companies Mentioned25

Related Topics

Related Reports

Pharmacovigilance Market Size, Share, Trends and Forecast by Service Provider, Product Life Cycle, Type, Process Flow, Therapeutic Area, End Use, and Region, 2025-2033 - Product Image

Pharmacovigilance Market Size, Share, Trends and Forecast by Service Provider, Product Life Cycle, Type, Process Flow, Therapeutic Area, End Use, and Region, 2025-2033

  • Report
  • 144 Pages
  • Global
From
Pharmacovigilance Market Size, Share & Trends Analysis Report By Product Life Cycle, By Service Provider (In-house, Contract Outsourcing), By Type, By Therapeutic Area, By Process Flow, By End Use, By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Pharmacovigilance Market Size, Share & Trends Analysis Report By Product Life Cycle, By Service Provider (In-house, Contract Outsourcing), By Type, By Therapeutic Area, By Process Flow, By End Use, By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 120 Pages
  • Global
From
Pharmacovigilance Market Report 2025 - Product Image

Pharmacovigilance Market Report 2025

  • Report
  • 250 Pages
  • Global
From
Post-Marketing Pharmacovigilance and Medical Information Market - Global Strategic Business Report - Product Image

Post-Marketing Pharmacovigilance and Medical Information Market - Global Strategic Business Report

  • Report
  • 285 Pages
  • Global
From
Pharmacovigilance - Global Strategic Business Report - Product Image

Pharmacovigilance - Global Strategic Business Report

  • Report
  • 473 Pages
  • Global
From

About the Pharmacovigilance Market

The Pharmacovigilance market is a subset of the Healthcare Services industry, focusing on the monitoring and assessment of the safety of pharmaceutical products. It involves the collection, analysis, and reporting of adverse events related to the use of drugs, as well as the identification of potential risks associated with their use. Pharmacovigilance activities are conducted by pharmaceutical companies, regulatory authorities, and healthcare professionals. Pharmacovigilance activities are essential for the safe and effective use of drugs, as they help to identify potential risks and ensure that the benefits of the drug outweigh the risks. Pharmacovigilance also helps to ensure that the drug is used appropriately and that any adverse events are reported and addressed. Some companies in the Pharmacovigilance market include Parexel, Quintiles, Covance, PRA Health Sciences, and ICON. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.